At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 11 enrolled
Drug / intervention
sofosbuvir/velpatasvirdrug
Likely dose
sofosbuvir/velpatasvir 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Bridging Care to HCV Treatment Among Opiate Dependent Patients on Buprenorphine/Naloxone Maintenance Therapy: A Pilot Study of Treating HCV With Epclusa at a Psychiatrist-staffed Outpatient Addiction Clinic
In Brief
A Phase 4 clinical trial evaluating sofosbuvir/velpatasvir for Hepatitis C, Chronic and 2 related conditions. Completed, enrolled 11 participants across 1 site.
Detailed Summary
The main purpose of this pilot study is to investigate the safety, effectiveness and tolerability of the study medication in the treatment of people with chronic hepatitis C virus infection who regularly attend a psychiatrist-staffed clinic for opiate addiction treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, Chronic, Hepatitis C, Opiate Dependence
CountriesUnited States
CollaboratorsGilead Sciences
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedAug 2017
Enrollment StartOct 2017
Primary CompletionSep 2019
TodayJul 2026
First PostedAug 1, 2017
Enrollment StartOct 11, 2017
Primary CompletionSep 26, 2019
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 8.9 years ago
Interventions
sofosbuvir/velpatasvirdrug
12 week treatment with once daily sofosbuvir/velpatasvir fixed dose combination therapy. Tablets are formulated with 400mg sofosbuvir and 100mg velpatasvir in pink, diamond-shaped, film coated tablets.